Showing 1411-1420 of 2656 results for "".
- Roche’s Actemra Gains FDA Emergency-Use in Hospitalized COVID-19 Patientshttps://modernod.com/news/roches-actemra-gains-fda-emergency-use-in-hospitalized-covid-19-patients/2479324/The FDA announced that it issued an emergency-use authorization (EUA) to Roche’s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and paediatric patients, according to FirstWord. Specifically, the IL-6 receptor antagonist is cleared for use in people who are receiv
- FDA Authorizes Pfizer, BioNTech’s COVID-19 Vaccine for Younger Adolescentshttps://modernod.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/The FDA on Monday expanded the emergency-use authorization (EUA) for Pfizer and BioNTech’s vaccine BNT162b2 to include preventing COVID-19 in adolescents 12 through 15 years of age, according to a FirstWord report. The two-dose mRNA-based vaccine was initially granted an EUA in December for
- EMA’s Blood Clot Review Exonerates AstraZeneca COVID-19 Vaccine, But Monitoring Continueshttps://modernod.com/news/emas-blood-clot-review-exonerates-astrazeneca-covid-19-vaccine-but-monitoring-continues/2478990/The European Medicines Agency (EMA) on Thursday said a review by its Pharmacovigilance Risk Assessment Committee (PRAC) has determined that AstraZeneca’s COVID-19 vaccine AZD1222 is safe and effective at preventing COVID-19, and that its benefits are “far greater” than any poten
- EMA Continues Safety Probe of AstraZeneca’s COVID-19 Vaccine as More Countries Halt Usehttps://modernod.com/news/ema-continues-safety-probe-of-astrazenecas-covid-19-vaccine-as-more-countries-halt-use/2478974/The European Medicines Agency (EMA) said it continues to investigate a number of thromboembolic events in people administered AstraZeneca’s COVID-19 vaccine AZD1222, whilst continuing to back the benefits of the immunization. The probe comes as a number of major EU nations, including France
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- Early Data Find AstraZeneca’s COVID-19 Vaccine Effective Against Fast-Spreading UK Strainhttps://modernod.com/news/early-data-find-astrazenecas-covid-19-vaccine-effective-against-fast-spreading-uk-strain/2478839/A preliminary analysis suggests that AstraZeneca’s AZD1222 vaccine is effective against COVID-19 caused by the highly-transmissible UK variant, according to a statement Friday by its partners at the University of Oxford. The findings, which are not peer-reviewed and were released as a prepr
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after